The best way to invest in
Biotechnology
Access the companies developing breakthrough therapies at the frontier of genetic medicine, immunology, and rare disease treatment. Biotechnology is one of the most innovative sectors in healthcare, with significant upside potential from clinical trial successes and drug approvals.
Read more
3.3%* 5Y annualised returns
250+ biotech and pharmaceutical companies
Sign up and invest with free buy orders
We’re licensed by the Securities Commission Malaysia (Licence eCMSL/A0352/2018)
RETURNS DATA
Backed by the companies curing tomorrow's diseases: 3.3%* 5Y annualised returns
If you had invested in the Biotechnology from July 2021 to July 2026, your money could have grown by around 18%.
1 Year Returns
Loading...
Loading...
Loading...
Disclaimer
Create your Biotechnology portfolio
StashAway ETF Explorer is the smart way to invest in 90+ global asset classes, including Biotechnology.
It's cost-effective
- Start investing today to get unlimited free buy orders for your next month.
- After, it's only $1.99 USD per buy or sell order, excluding SST.
- No additional management fee, no matter how much you invest.
It's simple
- Build your portfolio in as little as 1 minute.
- Automate recurring investments for ease of mind.
- No minimum balance, no lock-ins, and high liquidity mean you can access your funds anytime.
It's intelligent
- Our investment team analyses thousands of ETFs to identify cost-efficient, tax-efficient, and well-managed options.
- We swap underlying ETFs if a better alternative surfaces, saving you more over time.
GET STARTED WITH FREE BUY ORDERS
Own biotechnology stocks with one investment
Invest in the companies developing tomorrow's most important medicines
Asset Class Overview
Biotechnology Snapshot
Key information across returns, asset class profile, and investment details.
Returns
Annualised since inception
+7.42%
Since 28 February 2001
5-year annualised
+3.30%
Since 30 June 2021
1-year annualised
+48.49%
Since 30 June 2025
Year-to-date
+12.41%
Since 2026
Positive years since inception
75.00%
of calendar years
Fund Profile
Asset type
Equities
Fund inception
2001
Fundamentals
Expense ratio
0.44%
Annual ETF expense ratio
1-year dividend yield
0.22%
Trailing 12-month yield
Currency denomination
USD
US Dollar
Disclaimer
RETURNS DATA
Annual returns since 2001
Growth driven by America's leading biotechnology companies
Did you know?
The mRNA technology platform used to develop COVID-19 vaccines in record time was originally pioneered by researchers studying cancer treatment decades before the pandemic — demonstrating how foundational biological research can rapidly translate into life-saving applications. The biotechnology sector has produced some of the most dramatic stock price movements in financial markets: successful drug trial results can double or triple a company's value overnight, while failed trials can erase most of it. US biotechnology companies invest more in research and development relative to revenue than almost any other industry, making the sector one of the most innovation-intensive in the global economy.
PORTFOLIO BREAKDOWN
Sector exposure
Consumer, Non-cyclical
99.9%
Industrial
0.0%
Basic Materials
0.0%
Source: Bloomberg. Weights are approximate and subject to change on index rebalance.
PORTFOLIO BREAKDOWN
Geographic exposure
EXPLORE MORE
Other asset classes available
Other investors who viewed Biotechnology also explored these
